Aprea Therapeutics to Participate in the 2022 Wedbush PacGrow Healthcare Conference

On August 2, 2022 Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics targeting DNA damage response pathways, reported that Oren Gilad Ph.D, President and Chief Executive Officer, will participate in a panel discussion on synthetic lethality at the 2022 Wedbush PacGrow Healthcare Conference on Tuesday, August 9, 2022 at 12:35 p.m. ET (Press release, Aprea, AUG 2, 2022, View Source [SID1234617257]). The panel discussion will be hosted by Robert Driscoll, Ph.D. Senior Vice President, Healthcare Equity Research Wedbush PacGrow Lifesciences.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

Schedule Your 30 min Free Demo!

Use the contact form at the top or bottom of this page to book a free demo to 1stOncology™, an all inclusive cancer drug development intelligence platform from BioSeeker. The platform provides value in oncology for you in areas such as:

Target scouting
Indication selection & expansion
Combinatorial drug settings
Drug repositioning
First in class analysis
Compound cross over analysis
Competitive analysis
Pathway analysis

and much more...

1stOncology is recognized as a
Top 10 Global Pharma Analytic Provider

Continue your journey with 1stOncology by accessing our Free Leading Cancer Conference Whitepapers, signing up for our Free Weekly Newsletter and requesting a Free Demo to see how we can help you be 1st in Oncology!